Wedbush analyst Liana Moussatos reiterated a Buy rating on Albireo Pharma (ALBO – Research Report) today and set a price target of $84.00. The company's shares closed last Friday at $22.23, close to its 52-week low of $20.30. According to TipRanks.com, Moussatos ' ranking currently consits of 0 on a 0-5 ranking scale, with an average return of -4.0% and a 33.0% success rate. Moussatos covers the Healthcare sector, focusing on stocks such as Global Blood Therapeutics, BioMarin Pharmaceutical, and Pacira Pharmaceuticals. The word on The Street in general, suggests a Strong Buy analyst consensus rating for Albireo Pharma with a $76.00 average price target, representing a 249.4% upside.
https://www.tipranks.com/news/blurbs/wedbush-thinks-albireo-pharmas-stock-is-going-to-recover-3?utm_source=advfn.com&utm_medium=referral
Albireo Pharma (NASDAQ:ALBO)
Historical Stock Chart
Von Apr 2022 bis Mai 2022 Click Here for more Albireo Pharma Charts.
Albireo Pharma (NASDAQ:ALBO)
Historical Stock Chart
Von Mai 2021 bis Mai 2022 Click Here for more Albireo Pharma Charts.